Dementia Drugs, Treatments and Trials
For Dementia globally, treatments vary by country with wealthier nations like the US and those in Europe having more advanced drugs, while poorer areas tend to focus on basic support. New drugs being worked on aim to slow the disease and not just treat the symptoms. Dementia Hub looks at current options in the UK and worldwide, plus we assess the current drugs in trials and when they might be available to the general public.
As previously mentioned, early diagnosis is key. Tests include memory checks, brain scans, and blood tests. In 2025, blood tests for Alzheimer's are becoming more common, helping spot the disease sooner. Support for carers is vital, as dementia affects families too. Charities and groups like Alzheimer's Society can offer advice and support via their helplines.
Living well with dementia means staying active, eating well, and keeping social ties. Simple changes like using memory aids or joining groups can often help. Research is steadily speeding up, with many governments around the World now pledging more funds to help assist in fighting the disease rather than just treating conditions. One of the big aims within the UK is to improve diagnosis rates, currently at about 65% which is not high enough. Where possible, we will try and use simple words to explain complex ideas.
Current Drugs and Treatments in the UK
In the UK, dementia care focuses on managing symptoms and supporting daily life. The NHS handles most cases, but private options exist for those who can pay. Let's break it down.
NHS Treatments
The NHS offers free treatments based on need. There's no cure, but drugs and therapies help.
Symptom-Managing Drugs
Four main drugs are approved:
- Donepezil (Aricept): A brain booster for mild to severe Alzheimer's. It raises levels of a chemical called acetylcholine, helping brain cells talk better. Taken as a pill once a day. Side effects include feeling sick or tired, but these often fade.
- Rivastigmine (Exelon): Another brain booster for mild to moderate Alzheimer's, plus dementia with Lewy bodies. Comes as pills, liquid, or skin patches. Patches suit those who forget pills. Side effects: upset stomach or skin irritation from patches.
- Galantamine (Reminyl): For mild to moderate Alzheimer's. Like the others, it boosts acetylcholine. Available as pills or liquid. Side effects similar to donepezil.
- Memantine (Namenda): For moderate to severe Alzheimer's, or when brain boosters don't work. It blocks excess glutamate, a chemical that can harm brain cells. Taken as pills. Side effects: headaches or dizziness.
These drugs don't stop dementia but can improve thinking and memory for 6-12 months. They're prescribed by specialists after tests. For vascular dementia, drugs treat underlying issues like high blood pressure, such as ACE inhibitors or statins.
For tough behaviours like agitation, drugs like risperidone or haloperidol are used short-term under strict rules. They're only for severe cases and reviewed often due to risks like strokes.
New drugs like lecanemab and donanemab target amyloid plaques in Alzheimer's. They're approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) but not by NICE for NHS use. NICE says they're not cost-effective – lecanemab costs £20,000 a year, plus scans and infusions. So, not on NHS yet.
Non-Drug Options
NHS provides therapies:
- Cognitive Stimulation Therapy (CST): Group sessions with puzzles and talks to boost memory. Lasts 7 weeks, twice weekly. Evidence shows it helps mild dementia.
- Cognitive Training: One-on-one exercises on computers or apps to sharpen skills.
- Cognitive Rehabilitation: Working with therapists to meet goals, like cooking safely.
- Reminiscence Therapy: Sharing old photos or music to lift mood.
Other support: occupational therapy for home aids, physiotherapy for movement, and speech therapy for talking. NHS also funds care homes if needed.
Access starts with a GP referral to memory clinics. Diagnosis rates hit records in 2025, with over 70% of expected cases identified.
Blood tests for diagnosis are rolling out, speeding things up.
The government's 10-Year Health Plan promises more dementia focus, like better diagnosis and carer support.
Private Treatments
Private care offers the same drugs but faster. No long waits for scans or specialists. Costs: consultations £200-£500, drugs extra. These private clinics like Dementech or Cleveland Clinic London can also prescribe the four main drugs, plus new ones like lecanemab if you are able to pay.
- Lecanemab: available privately at places like Re:Cognition Health. It slows Alzheimer's by 27% in trials, but needs IV infusions every two weeks and brain scans for side effects like swelling.
- Donanemab: a similar drugs that clears plaques faster but has risks like brain bleeds. Private costs including monitoring are around £25,000-£40,000 yearly putting this option out of the reach of many.
Private therapies include advanced options like transcranial magnetic stimulation (TMS), which uses magnets to stimulate brain areas. Not standard on NHS yet. Home care packages are tailored, with nurses visiting.
Insurers may cover some, but new drugs often aren't. Private diagnosis is quicker – weeks vs. months on NHS.
In 2025, private sector grows as NHS faces backlogs. But it's not for everyone due to cost.
Comparing NHS and Private
NHS is free but slower. Private is fast but expensive. Both use MHRA-approved drugs. For new treatments, private leads. Government pushes for NHS access to innovations, but cost blocks it.
Support groups can often bridge gaps in both support and access to new drug trials and information. Alzheimer's Society runs dementia cafes nationwide.
Dementia Drugs and Treatments Worldwide
Dementia care differs across the World. As you would expect, richer countries generally have more access to drugs both public and privately funded, whilst the poorer World countries tend to focus on community support.
Let's look at key regions.
United States
The US leads in new drugs. The Food and Drug Administration (FDA) approves treatments faster than Europe.
Approved drugs include the same as the UK with donepezil, rivastigmine, galantamine, and memantine. Additionally combinations like Namzaric (memantine + donepezil).
New anti-amyloid drugs: lecanemab (Leqembi, 2023) and donanemab (Kisunla, 2024). They slow mild Alzheimer's by removing plaques. Lecanemab approved for IV maintenance in 2025.
Costs: $26,500 yearly for lecanemab, covered by Medicare for some.
Non-drug options include cognitive therapies, plus lifestyle programs like exercise classes. Private insurance varies and many who can afford to, pay out-of-pocket.
Over 6 million Americans have dementia. Research is strong, with NIH funding trials.
Europe and EU: These countries follow the European Medicines Agency (EMA) and drugs tend to match the UK's, however access can vary.
Germany: Strong NHS-like system covers drugs fully. New drugs like lecanemab available soon after approval.
France: Similar drugs; focuses on home care. Semaglutide (diabetes drug) tested for dementia benefits.
Scandinavia: High diagnosis rates, emphasis on social care. Norway uses tech like GPS trackers.
New drugs roll out slower than US due to cost checks.
Asia
- Japan: Lecanemab developed here by Eisai. Approved in 2023, widely used. Ageing population drives research.
- China: Leqembi approved in 2025.
Traditional herbs like ginkgo used alongside Western drugs. Over 10 million cases; focus on family care.
India: Basic drugs available cheaply. Private clinics offer advanced options in cities. Public health focuses on prevention via diet.
Australia and Canada
Australia: PBS subsidises drugs like donepezil. Lecanemab approved in 2024, but high cost limits use.
Canada: Similar to UK; new drugs under review. Emphasis on indigenous communities' needs.
Developing Countries
In Africa and Latin America there are few specialist drugs with the focus shifted to community support, education, and treating risks like diet and hypertension.
Global trends: Anti-amyloid drugs have recently sparked a large amount of hope but with costs exceeding $20,000+, and the risks which include brain swelling, mean that this option is not available for everybody.
Repurposed drugs like cancer meds (letrozole) show promise.
Worldwide, 138 new drugs in pipeline.
Dementia Trial Phase Drugs
Dementia touches millions of lives globally, with no complete cure in sight. Scientists worldwide are busy testing new drugs to slow it down or stop it altogether. Most efforts centre on Alzheimer's, the most common form. In 2025, there are 182 active trials checking 138 unique drugs. These trials fall into three stages. Phase 1 tests safety in small groups, Phase 2 checks if the drug works in bigger groups and Phase 3 confirms results in large crowds before approval.
About one-third of trials span the globe, involving places like North America, Europe, and Asia. Drug companies fund most, but Governments and charities chip in. Over 50,000 people will join these trials. One in three drugs comes from reusing meds for other illnesses, which speeds things up and cuts costs.
Trials use brain scans, blood tests, and other tools to pick the right people and track progress. They target brain issues like sticky plaques (amyloid), twisted proteins (tau), swelling (inflammation), or weak brain links (synapses). Some drugs boost thinking or calm tough moods. The pipeline grew by 9% from 2024, with more early-stage work. This brings hope for better treatments soon.
Phase 3 Trials: Nearest to Market
Phase 3 has 48 trials testing 31 drugs. These are the biggest studies, needing over 33,000 people. Most of these trials last one to three years. Two-thirds target the disease itself, like clearing plaques or fixing brain energy where others improve thinking or ease symptoms like agitation.
Key drugs include:
- Donanemab: A shot that clears amyloid plaques. Made by Biogen and Eisai, it slows early Alzheimer's.
- Lecanemab: Another shot against amyloid. From Eisai and Biogen, it reduces plaques and slows decline.
- Semaglutide: A reused diabetes pill that boosts brain health through better energy use. Novo Nordisk runs global tests.
- Dextromethorphan plus Quinidine: Helps with agitation. It calms brain signals and is reused from cough meds.
- Xanomeline plus Trospium: Eases psychosis. It targets brain receivers but adds a helper to cut side effects.
- Nabilone: A cannabis-based pill for agitation, hitting mood receivers.
- Simufilam: An oral drug that strengthens brain links for better thinking.
Twelve drugs are reused, making up nearly 40% here. Most trials are global, with sites in multiple countries for diverse testing and about 75% are backed by industry. Treatment times can vary: small pills for about a year, shots for longer. If any current trials are successful it is hoped that these could hit user markets by 2026 - 2027.
Phase 2 Trials: Gathering Proof
Phase 2 as of October 2025 currently features 86 trials with 75 drugs, involving around 13,700 people. Four in five target the disease core. More pills than shots here, with focus on swelling and plaques.
Standout examples:
- ALZ-801: An oral pill that stops amyloid clumping. Alzheon tests it for early cases.
- PBT2: Reused from other brain ills, it balances metals to fight amyloid.
- Blarcamesine: Boosts brain links via special receivers. Anavex aims at protection.
- NLX-112: Targets mood chemicals to lift thinking.
- Aducanumab: A shot clearing plaques, though it faced hurdles before.
- Gantenerumab: Roche's shot against amyloid plaques.
- E2814: Eisai's shot tackling tau twists.
Thirty-one reused drugs, over 40%. Half the trials are industry-led. Many are in North America only, but a quarter are global with trials lasting about a year for pills and longer for shots. Twenty-nine trials are due to end in 2025, hopefully paving the way for Phase 3.
Phase 1 Trials: First Safety Checks
Phase 1 as of the date of writing, has 48 trials with 45 drugs, needing about 2,800 people. Three-quarters target disease roots, these being split between pills and shots. The main focuses are on plaques, receivers, and swelling.
Notable ones:
- ABN-101: Reused from Parkinson's, fights amyloid.
- CT1812: Cuts swelling and stops tau clumping.
- PNSB201: Strengthens brain links.
- BIIB080: Biogen's shot against tau.
- UCB6240: UCB's shot clearing plaques.
- JNJ-548: Targets amyloid buildup.
- PTI-125: Reduces swelling in the brain.
Only seven are reused, the least here. Most trials are local, with over half in North America alone and can last from weeks to months. Growth doubled from 2024, showing fresh ideas flowing in.
Reused Drugs and Global Reach
Forty-six drugs are reused overall, from diabetes, cancer, or mood meds. This saves time since safety and side effects are generally well known.
Examples: Semaglutide for energy, PBT2 for metals. They make up 37% of trials.
Trials span 4,500+ sites worldwide. Phase 3 is most global (73%), ensuring drugs work for all backgrounds. North America leads, but Europe and Asia grow. Over 50,000 spots need filling, from healthy at-risk folks to those with severe dementia.
New Trends and Hopes
Biomarkers like blood tests for tau or amyloid help pick patients and measure wins. Over half of trials use them for entry, a quarter as main goals. Combo therapies rise: 20 trials mix drugs for better results, like fighting swelling two ways.
Targets diversify: 15 types, from gut-brain links to new growth. Early prevention trials (4%) aim at at-risk people before symptoms. Oral drugs (17 new) ease use.
Challenges remain: High costs, side effects like brain swelling. But with 120+ drugs total, breakthroughs loom. By 2030, several could change lives, slowing dementia for millions.
Researchers work hard to develop new drugs and run clinical trials to find better treatments. Funding for this important work comes from three main areas which are public sources, private investments, and charity donations. Public funding often comes from the government and supports large-scale projects. Private funding involves companies that hope to profit from new drugs in the future. Charity funding relies on public donations and focuses on innovative ideas. Dementia Hub explains each type of funding in detail and looks at how many people are involved in creating dementia drugs. Understanding these funding streams shows how the UK pushes forward in the fight against dementia.
Public Funding for Dementia Research
The government provides a large portion of funding for dementia drugs and trials through various organisations. The Medical Research Council, known as the MRC, is a key player in this area. It established the UK Dementia Research Institute in 2017 with an initial investment of £250 million.
This institute brings together experts to study the causes of dementia and develop new treatments. The MRC continues to support the institute with ongoing funds for research into drug development. For example, it recently committed £18 million for experimental medicine studies that explore new ways to tackle neurodegeneration.
These studies help scientists test potential drugs at an early stage.
Another important public body is the National Institute for Health and Care Research, or NIHR. This organisation funds clinical trials that test drugs on people with dementia. It has pledged up to £50 million for the UK Dementia Trials Network, which aims to speed up early-stage trials.
The NIHR also gave £20 million in 2024 to accelerate the translation of scientific discoveries into real treatments.
This money helps make trials more efficient and cost-effective for everyone involved.
The government launched the Dame Barbara Windsor Dementia Mission in 2022 to boost research efforts. This initiative has aligned up to £150 million in funding for various projects.
Part of this includes £20 million for a Dementia Trials Accelerator led by Health Data Research UK and the UK Dementia Research Institute.
This accelerator aims to enrol tens of thousands of patients in trials to test new drugs quickly.
Innovate UK, another government agency, has awarded £6 million to ten projects focused on detecting biomarkers for better clinical trials.
These public funds ensure that research is accessible and benefits the National Health Service in the long run.
Public funding also supports collaborations with other groups to maximise impact. For instance, the British Heart Foundation has funded a centre for vascular dementia research as part of the UK Dementia Research Institute.
This shows how government money can address specific types of dementia through targeted studies. Overall, public funding provides a stable base for long-term research into dementia drugs and helps cover costs that private or charity sources might not handle alone.
Private Funding for Dementia Research
Private companies play a crucial role in funding the development of dementia drugs and running clinical trials. Pharmaceutical firms like Eli Lilly and Eisai invest heavily in their own trials for drugs such as donanemab and lecanemab.
These companies develop the drugs and then fund large-scale tests to prove they are safe and effective. They sometimes provide grants or free drugs for trials run by independent researchers.
This approach helps bring new treatments to market faster than public funding alone could achieve.
Venture capital and private investors also contribute to early-stage drug discovery. For example, the Dementia Consortium is a partnership that includes private companies and charities.
This group funds projects up to £1 million to turn promising ideas into viable drugs.
Private funding often focuses on high-risk, high-reward research that could lead to profitable treatments. Companies like LifeArc have committed £30 million to the UK Dementia Research Institute for translational research.
This helps bridge the gap between lab discoveries and clinical trials.In recent years, private philanthropy has boosted funding for dementia trials. Gates Ventures partnered with Alzheimer's Research UK to launch the Dementia Frontiers Fund in 2025.
This global initiative aims to tackle roadblocks in research and speed up drug development.
Such funds provide flexible money for bold ideas that traditional sources might overlook. Private funding can cover the high costs of drug development, which charities alone cannot afford.
This includes expenses for advanced equipment and international collaborations.
Private sector involvement ensures that dementia research stays innovative and competitive on a global scale. For instance, companies sometimes repurpose existing drugs for dementia, funding trials to test their effectiveness.
This strategy reduces development time and costs while bringing potential treatments to patients sooner. Overall, private funding complements public efforts by focusing on commercial viability and rapid progress in drug creation.
Charity Funding for Dementia Research
Charities are vital in funding dementia drug development and clinical trials across the United Kingdom. Alzheimer's Research UK is one of the largest charity funders in this field and has invested £64.6 million in over 200 projects worldwide, including drug discovery and trials.
The charity offers grants like project funding for tenured researchers and fellowships up to £500,000.
It also runs the Global Clinical Trials Fund to support testing of new and repurposed drugs.
These funds help early-stage research that might lead to breakthrough treatments.
Alzheimer's Society also provides significant charity funding for dementia studies. It offers project grants, fellowships, and PhD studentships to support researchers. As a founding funder of the UK Dementia Research Institute, it contributes to the Care Research and Technology Centre.
The society focuses on partnerships to amplify its impact on drug trials. For example, it works with other groups to fund studies on repurposed drugs like semaglutide.
Charity money often goes to innovative projects that public funds might not cover.
Other charities like Race Against Dementia offer fellowships worth up to £500,000 for up to five years. This includes salaries, equipment, and travel for researchers working on drug development.
Parkinson's UK has invested £10 million in a new research centre at the UK Dementia Research Institute in 2025.
These funds target specific aspects of dementia, such as links to other conditions. Charities act as honest brokers, connecting academics with private companies for better trial outcomes.
Charity funding relies on public donations and events to sustain research efforts. For instance, Alzheimer's Research UK's Inspire Fund provides up to £5,000 for public engagement projects related to dementia.
This helps build awareness and attract more funds for drug trials. Overall, charities fill gaps in funding and drive progress toward new dementia treatments.
People Working on Creating Dementia Drugs
Many dedicated people work on creating dementia drugs in the United Kingdom. The UK Dementia Research Institute alone employs over 700 researchers at full strength across its centres.
This number has doubled since the institute started, showing growth in the field.
Alzheimer's Research UK supports hundreds more through its 200 funded projects.
In total, estimates suggest over 1,000 researchers work on dementia in the UK, though exact figures vary.
This includes scientists in academia, pharma companies, and charities focused on drug development.
These funding sources work together to advance dementia research and bring hope to affected families. With continued support, the UK can lead in developing effective drugs and improving lives.
Dementia Drugs Summary
As of the end of October 20205 there are currently over 180 trials testing 138 drugs, an increase of 9% from last year. Most current drugs and trials target Alzheimer's plaques, twists, swelling, or weak links with most trials needing over 50,000+ people.
Phase 3 (48 trials, 31 drugs):
These are the drugs and trials that are closest to the point of delivery for the general public. Donanemab and lecanemab expand tests. Semaglutide (diabetes pill) fights swelling. Simufilam fixes links. Twelve of these trials are expected to finish in 2025 and could be approved for use by 2026-27.
Phase 2 (86 trials, 75 drugs): Builds proof. ALZ-801 blocks clumps orally. Blarcamesine boosts links. Many pills for ease.
Phase 1 (48 trials, 45 drugs): Safety first. CT1812 cuts swelling. New focuses like gut-brain ties.Prevention trials (4%) test in at-risk folks. Combos and oral options rise. Challenges: Costs, side effects. But hope grows for slowdowns by 2030.
As case numbers grow the need for faster and effective research becomes more apparent and Dementia drugs are evolving fast offering hope to millions around the World. The current set of drugs help sufferers with daily life and trials offer the promise of real differences through halting and potentially reversing some of the disease.
Again, it is imperative that early signs of Dementia are spotted and acted up on together with lifestyle changes that are made for the better.